In 2022, the global Radiation-Induced Myelosuppression Treatment Industry achieved sales of US$ 2.9 billion. With a consistent 3.1% compound annual growth rate (CAGR), the market is on a trajectory to surpass US$ 3.5 billion in valuation by 2028.

The report tracks key factors driving revenue growth of the market –

  • Increasing prevalence of cancers
  • Early diagnosis, promises improved chances of positive outcomes
  • Fostering R&D funds supporting cancer research
  • Strong product pipeline
  • Bolstering adoption of chemo-radiotherapy in cancer treatment

Request a Sample Copy of the Report Now
https://www.futuremarketinsights.com/reports/sample/rep-gb-8116

Against the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of the product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.

  • Myelo001 by Myelo Therapeutics GmbH recently received FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.
  • Mylan NV and Pfizer Inc. also received FDA approvals for their recently launched biosimilars – Epogen Neupogen, and Neulasta respectively.

The patent expiry of originator biologics formulations is creating investment opportunities in biosimilar production – for the operators in the radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.

Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the radiation-induced myelosuppression treatment industry in the region. North America will reportedly continue to account for over 65% share of the global market value.

New product launches currently mark the top developmental strategy adopted by leading companies competing in the radiation-induced myelosuppression treatment industry. A majority of key players are also identified to focus on enhancing their geographical foothold in the global radiation-induced myelosuppression treatment landscape.  The report in a distinct section covers some of the key competitors operating in the radiation-induced myelosuppression treatment marketplace, emphasizing their financial as well as strategic profiles in depth.

Delving into the study’s assumptions. Ask the analyst now
https://www.futuremarketinsights.com/ask-question/rep-gb-8116

A few of the profiled companies include Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC (Johnson & Johnson), Amgen Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, and Partner Therapeutics, Inc.

In the highly consolidated competitive landscape of global radiation-induced myelosuppression treatment, the three top-ranking companies, i.e. Janssen Pharmaceutical NV, Amgen Inc., and Teva Pharmaceutical Industries Ltd. dominate in terms of market value. These players continue to hold winning revenue shares in the radiation-induced myelosuppression treatment owing to a strong global presence and a considerable number of new drug approvals. Established companies are entering strategic partnerships and collaborations with regional leaders, to achieve better penetration into regional markets.

Radiation-Induced Myelosuppression Treatment Market by Category

Indication: 

  • Neutropenia
  • Anemia
  • Thrombocytopenia

Drug Class:

  • Growth factors
  • Erythropoietin stimulating agents
  • Thrombopoietin agents
  • Iron supplements

Route of Administration:

  • Oral
  • Injectable

Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Drug stores

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Gain the Edge with Segmented Information – Buy Now!
https://www.futuremarketinsights.com/checkout/8116

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Leave a comment

Your email address will not be published. Required fields are marked *